NetMed, Inc., a developer and marketer of medical and health-related technologies, announced the commencement of a multicenter US clinical trial of the PAPNET cervical cancer detection system as a primary screening test for Pap smears. The trial is being sponsored by Neuromedical Systems, Inc., developer of the PAPNET system, which expects to complete the trial in early 1999.
The clinical trial is expected to demonstrate substantially improved specificity and sensitivity for both conventionally prepared Pap smears and liquid-based preparations, when compared to current manual screening methods.
"This is a significant milestone for the technology and our business," stated David J. Richards, president and CEO of NetMed. "NSIs worldwide results to date with primary screening give us optimism that this trial will prove successful.